3D-printed/electrospun bioresorbable nanofibrous drug-eluting cuboid frames for repair of alveolar bone defects

被引:15
作者
Chou, Pang-Yun [1 ,2 ,3 ]
Lee, Demei [1 ]
Chen, Shih-Heng [2 ,3 ]
Liao, Chien-Tun [1 ]
Lo, Lun-Jou [2 ,3 ]
Liu, Shih-Jung [1 ,4 ]
机构
[1] Chang Gung Univ, Dept Mech Engn, Taoyuan 33302, Taiwan
[2] Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Taoyuan 33305, Taiwan
[3] Chang Gung Mem Hosp, Craniofacial Res Ctr, Taoyuan 33305, Taiwan
[4] Chang Gung Mem Hosp Linkou, Dept Orthoped Surg, Bone & Joint Res Ctr, Taoyuan 33305, Taiwan
关键词
Alveolar bone repair; Drug-eluting cuboid frames; Nanofibers; 3D printing; Electrospinning; 3D PRINTING TECHNOLOGY; KETOROLAC;
D O I
10.1016/j.ijpharm.2022.121497
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite progress in clinical science, the repair and restoration of alveolar bone defects remains as a challenge, particularly for nonuniform and complex defects. We developed bioresorbable nanofibrous drug-eluting cuboid frames for alveolar bone repair using three-dimensional (3D) printing and electrospinning technologies. The cuboid frames comprised polylactide (PLA) cages and ketorolac and amoxicillin-loaded poly(lactic-co-glycolic acid) nanofibers that imitated the morphology of the natural extracellular matrix of bone tissues. Characteristics of the printed frame and electrospun nanofibers were evaluated. The in vitro and in vivo release characteristics of the drugs embedded in the nanofibers were estimated using a high-performance liquid chromatography assay. In addition, the in vivo efficacies of the PLA cuboid frame and drug-eluting nanofibers for the treatment of alveolar bone defects were evaluated in a rat model. The experimental data indicated that the nanofibrous PLA frame provided a sustained release of ketorolac and amoxicillin for over 4 weeks. The results of the in vivo animal test also indicated that the animals that were implanted with the drug-eluting cuboid frame exhibited significantly greater movement than the animals with no frame. Histological analysis revealed no sign of adverse effects of the drug-eluting frames. By adopting 3D printing and electrospinning technologies, resorbable drug-eluting cuboid frames can be successfully manufactured for maxillofacial applications.
引用
收藏
页数:9
相关论文
共 34 条
[1]  
Aronson J. K., 2016, Meylers Side Effects of Drugs. 16th ed. Elsevier, P132
[2]  
Baraka M.M., 2014, Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry, V2, P197
[3]   Preparation and Physicochemical Characterization of Amoxicillin β-cyclodextrin Complexes [J].
Bisson-Boutelliez, Catherine ;
Fontanay, Stephane ;
Finance, Chantal ;
Kedzierewicz, Francine .
AAPS PHARMSCITECH, 2010, 11 (02) :574-581
[4]   Comparative Volume Analysis of Alveolar Defects by 3D Simulation [J].
Chou, Pang-Yun ;
Denadai, Rafael ;
Hallac, Rami R. ;
Dumrongwongsiri, Sarayuth ;
Hsieh, Wei-Chuan ;
Pai, Betty C. J. ;
Lo, Lun-Jou .
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (09)
[5]  
Coots Bradley K, 2012, Semin Plast Surg, V26, P178, DOI 10.1055/s-0033-1333887
[6]   Skeletofacial Reconstruction for Cleft-Related Deformities Four Decades of Evolving Cleft Care [J].
Denadai, Rafael ;
Chou, Pang-Yun ;
Pai, Betty C. J. ;
Chen, Chit ;
Lin, Clement Cheng-Hui ;
Huang, Chiung-Shing ;
Chen, Yu-Ray ;
Lo, Lun-Jou .
ANNALS OF PLASTIC SURGERY, 2020, 85 (01) :3-11
[7]   Applications of PLA in modern medicine [J].
DeStefano V. ;
Khan S. ;
Tabada A. .
Engineered Regeneration, 2020, 1 :76-87
[8]   Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies [J].
Fathalla, Zeinab M. A. ;
Vangala, Anil ;
Longman, Michael ;
Khaled, Khaled A. ;
Hussein, Amal K. ;
El-Garhy, Omar H. ;
Alany, Raid G. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2017, 114 :119-134
[9]  
Gaertner DJ, 2008, AM COLL LAB, P239, DOI 10.1016/B978-012373898-1.50014-0
[10]   Poly(lactic-co-glycolic) Acid-Controlled-Release Systems: Experimental and Modeling Insights [J].
Hines, Daniel J. ;
Kaplan, David L. .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2013, 30 (03) :257-276